Merck KGaA stock (DE0006599905): Pharma and electronics player in focus after latest quarterly update

Merck KGaA has presented fresh quarterly figures and updated its outlook, putting the diversified pharma and electronics group back on the radar of international investors.

Merck KGaA has recently reported new quarterly figures and provided updates on its business outlook, giving investors fresh insights into the performance of its healthcare, life science and electronics divisions, according to Merck investor information as of 03/07/2025 and follow-up communications summarized by Reuters as of 03/07/2025.

As of: 15.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Merck KGaA
• Sector/industry: Healthcare, life science, electronics
• Headquarters/country: Darmstadt, Germany
• Core markets: Europe, North America, Asia
• Key revenue drivers: Pharmaceuticals, laboratory supplies, specialty materials for chips and displays
• Home exchange/listing venue: Xetra (ticker: MRK)
• Trading currency: EUR

Merck KGaA: core business model

Merck KGaA is a diversified science and technology company with three main pillars: healthcare, life science and electronics. In healthcare, the group focuses on prescription medicines for neurology, oncology and fertility, building on a long history in German pharmaceuticals while seeking growth in targeted specialty therapies, as highlighted in its annual reporting for 2024, according to Merck annual report information as of 03/14/2025.

The life science segment supplies laboratories and biopharmaceutical manufacturers with equipment, consumables and process solutions, ranging from chromatography materials to single-use systems. This unit has benefited in recent years from structural demand in biotech and vaccine production, although growth has normalized after the pandemic boom, as described in management commentary for 2024, according to Merck financial results overview as of 03/07/2025.

The electronics division (previously known as performance materials) supplies specialty chemicals and materials for the semiconductor and display industries. Products include high-purity gases, photolithography materials and liquid crystals used in displays and advanced chip production. This makes Merck an important supplier to global technology and consumer electronics companies, with revenue exposure to the US, Taiwan, South Korea and other key chip hubs.

Main revenue and product drivers for Merck KGaA

In the latest reported financial year 2024, Merck highlighted the importance of its life science unit as a revenue and profit driver, with this segment again contributing a significant share of group sales, according to figures and commentary in the 2024 annual report published in March 2025, as summarized by Merck 2024 annual report overview as of 03/14/2025. The portfolio ranges from research reagents to solutions for industrial-scale biopharmaceutical manufacturing, positioning the company along the entire value chain of modern medicine development.

Healthcare remains strategically important because it combines established products with potential growth from new specialty medicines. Key therapeutic areas include multiple sclerosis, oncology and fertility treatments. Patent cycles, competition from generics and pipeline execution are crucial factors for this division, and management has emphasized investments into research and development as a foundation for long-term value creation, according to Merck research overview as of 02/20/2025.

The electronics business is highly sensitive to investment cycles in the semiconductor and display industries. After a period of weakness in some display markets, Merck has been concentrating on higher-value products for advanced chips, including materials for EUV lithography and other leading-edge processes. Management commentary for 2024 pointed to early signs of a rebound in demand from semiconductor customers, according to Merck Q4 2024 results information as of 03/07/2025.

Why Merck KGaA matters for US investors

Although Merck KGaA is headquartered in Germany and primarily listed in Frankfurt, its products and technologies play a sizable role in the US healthcare and technology markets. The company generates a substantial portion of its revenue in North America through life science supplies, prescription medicines and materials sold to US semiconductor manufacturers, according to geographic breakdowns in its 2024 annual report published in March 2025, as referenced by Merck annual report 2024 as of 03/14/2025.

For US investors, the stock offers exposure to themes such as specialty pharmaceuticals, biotech infrastructure and semiconductor materials within a single European blue chip. Merck’s scale and diversified model can be relevant for portfolios seeking non-US issuers with meaningful operations in the United States, especially those tied to the long-term growth of biopharmaceutical research and advanced chip manufacturing, which are key components of the US economy.

Conclusion

Merck KGaA combines healthcare, life science and electronics under one roof, offering diversified exposure to pharmaceuticals, laboratory supplies and semiconductor materials. Recent financial updates underscore both the opportunities and cyclicality in its key markets. For internationally oriented US investors, the stock represents a significant European player linked to structural trends in medicine and advanced technology, but outcomes will continue to depend on execution in drug development, investment cycles in chips and global demand for lab and process solutions.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.